Authors


Daniel P. Petrylak, MD

Latest:

Optimization of Genetic Testing for mCRPC

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.


Daniel D. Rhoads, MD

Latest:

Diagnostic stewardship for urinary tract infection: A snapshot of the expert guidance

Urinary tract infections (UTIs) are among the most common human infections. But the urine culture, the cornerstone for laboratory diagnosis of UTI, is imperfect.


Thomas Lowrey, MD

Latest:

How to implement an ERAS pathway in your urology practice

Program encompasses patient counseling, anesthetic planning, and early mobilization.


Roger Dmochowski, MD, MA (Conflict Management and Resolution), MMHC, FACS

Latest:

The American Board of Urology: Considerations for the urologist in career transitions

"The ABU continues to reevaluate all policies related to diplomates. As medical practice continues to evolve in United States, and these changes affect the practitioners of medicine, likely further changes will be necessary in board certification procedures," writes Roger Dmochowski, MD, MA (Conflict Management and Resolution), MMHC, FACS.


UCI Health

Latest:

UCI receives renewal as Orange County’s only federally designated comprehensive cancer center

The National Cancer Institute has again recognized the UCI Chao Family Comprehensive Cancer Center as one of the nation’s top cancer centers, renewing its “comprehensive” designation


Rana R. McKay, MD

Latest:

GNRH agonists vs antagonists in prostate cancer: How to choose

Many factors play into decision-making process when weighing agents.


William C. Reha, MD, MBA

Latest:

Legislative efforts to eliminate barriers to prostate cancer screening ramp up

"Our success depends on your assertive action and membership in organizations serving our specialty—the AACU in particular—as well as your state medical association," writes William C. Reha, MD, MBA.


Brittany Lovely

Latest:

Erdafitinib nears EU approval for FGFR3-positive urothelial carcinoma

The positive CHMP opinion is supported by findings from cohort 1 of the phase 3 THOR trial.


Wayne Singer

Latest:

MIPS success: What specialists need to know

"Specialty providers can take three steps now to succeed with MIPS while prioritizing caring for their patients," writes Wayne Singer.


Thai Ho, MD, PhD

Latest:

Recognizing hereditary syndromes in renal cell carcinoma

Patients may require specific diagnostic, surveillance, and therapeutic management.


Alex Biese

Latest:

EBRT not linked to increased hematological toxicity for mCRPC treated with Ra-233

Drug-related hematological treatment-emergent adverse events were proportionately similar between the EBRT cohort and the those who did not receive EBRT to the bone.


Alice Li, PharmD

Latest:

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.


John Han-Chih Chang, MD

Latest:

Future Landscape of Prostate Cancer and Rectal Spacers

The expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.


Kristen R. Scarpato, MD, MPH

Latest:

Considerations for palliative care in urologic oncology

Benefits include improved quality of life and symptom management.


Michael Underhill, DO

Latest:

Physician Commentary: Do EHR upgrades really enhance patient care?

"Clinicians, now more than ever, have many data entry duties. The clinical encounter’s efficiency is dictated by the ease of the EHR," write Jesse D. Bracamonte, DO, FAAFP, and Michael Underhill, DO.


Vadim Khazan

Latest:

Considerations for choosing an AI scribe tool

AI scribe solutions are one of the easiest technologies to deploy into existing workflows, writes Vadim Khazan.


Amirali Salmasi, MD

Latest:

Key Takeaways on the Evolving NMIBC Treatment Landscape

The panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.


Judd W. Moul, MD

Latest:

EP. 1B: Advanced/Metastatic Prostate Cancer: Disease Overview, Treatment Strategies, and Unmet Needs

In this companion article, Judd W. Moul, MD, of Duke University Medical Center, shares expert insights into factors affecting treatment decisions in metastatic hormone-sensitive and castration-resistant prostate cancer.


Navid Leelani, DO

Latest:

Male sexual health and reproductive medicine: All that glitters is not gold

"With the average cost of treatment ranging from $2600 to $3900 per cycle, clinics offering radial wave therapy have an obvious financial incentive to continue marketing despite the lack of evidence of its effectiveness," write Navid Leelani, DO, and Scott D. Lundy, MD, PhD.


Stephanie Trexler, PharmD, BCOP

Latest:

Expert explains everything you need to know about lutetium Lu-177 vipivotide tetraxetan for mCRPC

"During treatment with 177Lu-PSMA-617, patients should be counseled to increase oral fluid intake and to void frequently to reduce bladder radiation exposure," writes Stephanie Trexler, PharmD, BCOP.


Megan Hollasch

Latest:

Understanding molecular phenotypes in RCC may help drive treatment decisions

Benjamin L. Maughan, MD, PharmD, highlights key studies presented at the 2024 ASCO Annual Meeting regarding biomarkers and the evolution of first-line treatments in renal cell carcinoma.


GenesisCare

Latest:

GenesisCare Enrolls First Patients to SpaceOAR Vue Hydrogel Global Clinical Trial

For the first time, the trial will examine the efficacy of SpaceOAR Vue Hydrogel in reducing late gastrointestinal toxicity and improving the quality of life in patients receiving stereotactic body radiotherapy for the treatment of prostate cancer.


Kelli Gross, MD

Latest:

Expert Forum: Fertility after exogenous testosterone replacement

Treatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.


Varun Sundaram, MD

Latest:

Future Landscape of Prostate Cancer and Rectal Spacers

The expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.


Oliver Sartor, MD

Latest:

Optimization of Genetic Testing for mCRPC

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.


Kara Hartl, MD

Latest:

Hybrid approach to telehealth effective in rural communities

“A hybrid telehealth approach expands access to specialized care, reduces travel burdens, promotes timely interventions, and enables continuous management of health conditions,” writes Kara Hartl, MD.


Jay D. Raman, MD, FACS

Latest:

Strategies to mitigate impact of intravenous ICM shortage

"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.


Oron Afek

Latest:

Expert examines tech-driven burnout in healthcare

“Health care technology has largely failed to deliver on its promise to make the management of patient care simpler, easier, and less stressful for clinicians,” writes Oron Afek.


Eric Demers

Latest:

What role can automation play in solving the prior authorization issue?

If automation can enhance efficiency and reduce provider dissatisfaction while improving patient health, there’s a strong case for introducing automation into the mix, writes industry expert Eric Demers.


Jim Brady

Latest:

Tax deduction can offset your practice’s cost for new equipment and technology

Section 179 of the IRS Tax Code allows businesses to deduct up to the full purchase price of qualified equipment, technology, software, and other qualifying purchases from their taxes within the same tax year.

© 2024 MJH Life Sciences

All rights reserved.